[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337779-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337779-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","t-cell-redirecting-bispecific-antibodies-a-review-of-a-novel-class-of-immuno-oncology-for-advanced-prostate-cancer","T-Cell redirecting bispecific antibodies - a review of a novel class of immuno-oncology for advanced prostate cancer","","Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are presented as emerging strategies for advanced prostate cancer. BiTEs are engineered antibodies with two binding domains that enable simultaneous engagement of tumor-associated antigens (e.g., PSMA, PSCA, hK2, STEAP1) and immune effector cells, promoting anti-tumor responses. Early BiTE constructs showed meaningful activity but faced limitations from delivery, immunogenicity, and adverse effects. The review summarizes recent clinical developments and evolving safety and efficacy data for advanced disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/t-cell-redirecting-bispecific-antibodies-a-review-of-a-novel-class-of-immuno-oncology-for-advanced-prostate-cancer/337779/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/t-cell-redirecting-bispecific-antibodies-a-review-of-a-novel-class-of-immuno-oncology-for-advanced-prostate-cancer/337779.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are T-cell redirecting bispecific antibodies (BiTEs) and how do they work in prostate cancer?","Question",{"text":63,"@type":64},"BiTEs are engineered bispecific antibodies with two binding domains that bind both tumor-associated antigens and immune effector cells simultaneously, driving immune recognition and attack of cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which tumor-associated antigens are highlighted as targets for prostate cancer BiTE therapies?",{"text":68,"@type":64},"The review mentions prostate cancer antigens including PSMA, PSCA, hK2, and STEAP1 as tumor-associated targets suitable for BiTE engagement.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges limited earlier BiTE constructs, and what is being done to address them?",{"text":72,"@type":64},"Earlier BiTEs were constrained by drug delivery issues, immunogenicity, and treatment-associated adverse effects; newer constructs aim to overcome these barriers while improving efficacy and safety.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337779,1790528868,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","REVIEW  \nT-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer  \nJulia Paleckia, Amman Bhasina, Andrew Bernsteina, Patrick J. Milleb, William J. Testerb, Wm. Kevin Kellyb, and Kevin K. Zarrabi b  \naDepartment of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA; bDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA  \nABSTRACT  \nNovel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as well as immune effector cells, thus promoting an immune response against cancer cells. Prostate cancer is rich in tumor associated antigens such as, but not limited to, PSMA, PSCA, hK2, and STEAP1 and there is strong biologic rationale for employment of T-cell redirecting BiTEs within the prostate cancer disease space. Early generation BiTE constructs employed in clinical study have demonstrated meaningful antitumor activity, but challenges related to drug delivery, immunogenicity, and treatment-associated adverse effects limited their success. The ongoing development of novel BiTE constructs continues to address these barriers and to yield promising results in terms of efficacy and safety. This review will highlight some of most recent developments of BiTE therapies for patients with advanced prostate cancer and the evolving data surrounding BiTE constructs undergoing clinical evaluation.  \nARTICLE HISTORY  \nReceived 7 January 2024 Revised 1 April 2024 Accepted 14 May 2024  \nKEYWORDS  \nProstate cancer; immunotherapy; Bispecific antibody; PSMA; STEAP1  \nIntroduction  \nProstate cancer (PCa) is the second most common cause of cancer-related death for men in the United States. 1 An estimated 288,300 new cases of PCa leading to 34,700 deaths occurred in 2023 in the United States.2 Localized PCa is often treated effectively with surgery and/or radiotherapy.3 Active surveillance can be considered in low-risk or select intermediate-risk patients.4, 5 Androgen ablation therapy remains the backbone oftherapy for metastatic disease, thoughthe development of castrate resistance is an inevitable reality for most patients.6 The incidence of metastatic castrateresistant prostate cancer (mCRPC) has increased in recent years and the disease remains incurable, despite ongoing advancements in treatment strategies improving survival.7 Androgen receptor signaling inhibitors and chemotherapeutic options such as taxanes have proven efficacy and can palliate disease as does radiotherapy with radium-233, though the long-term benefit is limited, and treatment-associated toxicity is abundant.8–10 More recently, PSMA-targeted radioligand therapies such as177Lu-PSMA-617 have demonstrated promising results and highlight the effective strategy of tailoring therapy to a selective tumor associated antigen. 11  \nImmunotherapies such as immune checkpoint inhibitors, which have revolutionized the treatment of certain solid tumors and hematologic malignancies, have demonstrated limited efficacy in patients with PCa. 12, 13 In recent years, T-cell engager immunotherapies including chimeric antigen  \nreceptor (CAR) T-cell therapies and bispecific T-cell engager (BiTE) therapies have emerged as promising modalities for the treatment a variety of hematologic malignancies, and hold promise of demonstrating efficacy in patients with PCa.14, 15 In this review, we highlight novel BiTE therapies under development for patients with PCa, focusing on early reports of their efficacy and tolerability. We aim to share our perspective on BiTE successes and pitfalls, as well as to reflect on how BiTE therapies will shape the future of the treatment of mCRPC.  \nT-cell redirection as an immunotherapeutic stra","cbCaiufph66nzif9","https://ap.wps.com/l/cbCaiufph66nzif9","pdf",379911,12,"English","# Introduction\n## T-cell redirection as an immunotherapeutic strategy","[{\"question\":\"What are T-cell redirecting bispecific antibodies (BiTEs) and how do they work in prostate cancer?\",\"answer\":\"BiTEs are engineered bispecific antibodies with two binding domains that bind both tumor-associated antigens and immune effector cells simultaneously, driving immune recognition and attack of cancer cells.\"},{\"question\":\"Which tumor-associated antigens are highlighted as targets for prostate cancer BiTE therapies?\",\"answer\":\"The review mentions prostate cancer antigens including PSMA, PSCA, hK2, and STEAP1 as tumor-associated targets suitable for BiTE engagement.\"},{\"question\":\"What challenges limited earlier BiTE constructs, and what is being done to address them?\",\"answer\":\"Earlier BiTEs were constrained by drug delivery issues, immunogenicity, and treatment-associated adverse effects; newer constructs aim to overcome these barriers while improving efficacy and safety.\"}]","T-Cell redirecting bispecific antibodies - a review of a novel class of immuno-oncology for advanced prostate cancer | PDF",1790020602,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f506278ad1bded1634a4744db27a2e70.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf314c9b09ccbff68de5e6bba1c72688.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b51431fa7dbef65144e2f501b41776f0.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5b483c749822e1e1b12f9c5ed242448.webp",980,1276]